Influenza virus with resistance to antiviral drugs emerges with increased frequency in immunocompromised patients and can limit the benefit of M2 and neuraminidase (NA) inhibitors. We document 3 cases of influenza in severely immunocompromised patients from whom virus variants with molecular markers of resistance to anti-influenza drugs were recovered. Virus variants recovered from 2 patients had mutations in the M2, NA (with a previously recognized Glu119Val NA substitution), and hemagglutinin genes. We describe a novel Asp198Asn NA mutation in an influenza B virus and its decreased susceptibility to both oseltamivir and zanamivir.
Influenza virus with resistance to antiviral drugs emerges with increased frequency in immunocompromised patients and can limit the benefit of M2 and neuraminidase (NA) inhibitors. We document 3 cases of influenza in severely immunocompromised patients from whom virus variants with molecular markers of resistance to anti-influenza drugs were recovered. Virus variants recovered from 2 patients had mutations in the M2, NA (with a previously recognized Glu119Val NA substitution), and hemagglutinin genes. We describe a novel Asp198Asn NA mutation in an influenza B virus and its decreased susceptibility to both oseltamivir and zanamivir.
Influenza causes significant morbidity and mortality in patients with compromised immune systems. Influenza virus infection in transplant recipients is associated with a higher rate of pulmonary complications (particularly viral pneumonia), extrapulmonary manifestations, an increased risk of graft dysfunction and rejection, and high attributable mortality [1] . In addition, transplant recipients have prolonged shedding of influenza virus, often despite antiviral therapy [2] , which promotes the emergence of antiviral resistance [3] . This is a wellrecognized problem with the use of the M2 inhibitors amantadine and rimantadine [1] but is an uncommon complication with the use of the neuraminidase (NA) inhibitors zanamivir and oseltamivir in adults [4] . In vitro resistance to NA inhibitors can be mediated by changes in hemagglutinin (HA), which confer crossresistance to the class in cell culture; changes in NA, which confers resistance that is NA subtype specific and drug specific; or changes in both [4] . Mutations in HA typically reduce HA binding efficiency, thus reducing the virus's dependency on its NA activity [4, 5] . In the present article, we describe the clinical and virologic characteristics of 3 immunocompromised patients who had progressive influenza virus infection despite NA inhibitor therapy with or without concurrent M2 inhibitor therapy.
METHODS
Cells, virus isolates, and compounds. MDCK cells grown in Eagle's MEM (EMEM) supplemented with 10% fetal bovine serum, antibiotics, and l-glutamine were used for virus propagation and for virus plaque purification (described below). Viruses were propagated by standard procedures, and aliquots were stored at Ϫ70ЊC [6] .
The clinical isolates (described below) were isolated initially in MDCK cells and passaged 1-2 times before analysis. The previously characterized NA inhibitor-resistant mutants Glu119Gly, Glu119Asp, and Arg292Lys of the influenza A/turkey/Minnesota/833/80 (H4N2) vi- rus [7, 8] and the mutant Arg152Lys of the influenza B/Memphis/ 20/96 [9] were from the virus repository of the Respiratory Disease Study Unit at the University of Virginia. Stock solutions of zanamivir (GlaxoSmithKline) and oseltamivir carboxylate (Hoffman-La Roche) were prepared in distilled water and frozen in aliquots at Ϫ20ЊC until they were thawed immediately before use. NA-inhibition assay. Evaluation of virus susceptibility to NA inhibitor was assessed in the NA enzymatic activity inhibition assay, as described elsewhere [4] . The IC 50 of NA inhibitors was calculated by plotting the percentage inhibition of NA activity against the inhibitor concentration.
Sequence analysis of the HA, NA, and M genes. Viral RNA was extracted from either original samples or cell culture supernatants, and reverse-transcription polymerase chain reactions and sequence analysis of the HA, NA, and M genes were performed as described elsewhere [4] . The sequences of primers used for PCR amplification are available on request. The sequence alignments were performed by use of the Influenza Sequence Database [6] . The nucleotide sequences were deposited into the GenBank database (accession numbers AY947469-AY947478).
RESULTS

Patient 1.
This 2-year-old white female patient developed myelomonocytic leukemia at 15 months of age and was treated by splenectomy and, later, by unrelated cord-blood marrow transplantation (on 25 January 2001). While receiving antithymocyte globulin and cyclosporine, the patient was started on a regimen of oseltamivir prophylaxis (10 mg orally twice daily) on posttransplantation day 15, after her mother received a clinical diagnosis of influenza. Four days after starting the oseltamivir regimen (day 21), the patient developed nasal congestion, nonproductive cough, and rhinorrhea; a nasopharyngeal swab culture was found to be positive for influenza B virus (designated B/Rochester/02/2001). The patient received 30 mg of oseltamivir twice daily for 2 weeks (until day 46), after which her dose was decreased to 20 mg twice daily for an additional 4 weeks. The patient had continued rhinorrhea and cough throughout but had transient resolution of fever during the second to third weeks of illness. She received aerosolized ribavirin from day 27 until day 33 and then intravenous ribavirin during the last 10 days of her illness (days 69-79). Despite therapy, she experienced progressive respiratory distress and gastrointestinal bleeding, and she eventually died.
Nine isolates of influenza B virus from the patient, recovered over a period of 1.5 months, were tested for susceptibility to NA inhibitors (table 1) . Virus recovered on day 42 (8 March 2001) had an ∼3-fold increase in the average IC 50 (table 1) Among the 5 isolates available for testing, the first was susceptible to both NA inhibitors (table 2) . NA gene analysis demonstrated a mixed population of wild-type virus and Glu119Val mutants during the second therapy course. The Glu119Val mutant was dominant in the next isolate and had 1100-fold increased IC 50 against oseltamivir but no significant change in IC 50 against zanamivir. This variant also had 3 amino acid substitutions in the HA, 2 of which (Arg142Gly and Tyr195Phe) reside near the receptor-binding site [10] . These mutant NA and HA genes were not detectable in later isolates. A Ser31Asn substitution in M2 persisted in all tested variants after 27 March 2002.
Patient 3. This 60-year-old white female patient underwent cadaveric renal transplantation for diabetic nephropathy on 6 November 2003 and was maintained on a regimen of tacrolimus, mycophenolate mofetil, and prednisone. At posttransplantation week 6, she developed fever, malaise, myalgias, arthralgias, minimally productive cough, and a pruritic rash. Evaluation revealed that the patient had both graft-versus-host disease with pancytopenia and influenza A virus (designated A/Charlottesville/03/ 2004 [H3N2]) infection determined by culture on 27 December 2003. Oral oseltamivir treatment (75 mg twice daily) was started, and the dose was subsequently increased to 150 mg twice daily for a total course of 18 days. However, she had progressive respiratory compromise and developed pneumonia by day 9 of therapy. Rimantadine was added to her treatment, but she had continued detection of influenza virus with respiratory failure and died after a hemorrhagic stroke. The 6 influenza isolates collected during her illness demonstrated a 1100-fold increase in the IC 50 against oseltamivir between the first (0.3 nmol/L) and the last (82.8 nmol/L) isolate, as well as a 3-fold increase in IC 50 against zanamivir (table 3) . Two mutations-Glu119Val in NA and Ser31Asn in M2-were detected in the last isolate. The HA of the oseltamivir-resistant mutant contained a substitution at aa 226 (ValrIle).
DISCUSSION
Antiviral therapy with either M2 inhibitors or NA inhibitors appears to reduce the duration of viral shedding, the risk of progression to pneumonia, and, possibly, the mortality associated with influenza in immunocompromised patients [1, 2, 11] . Unfortunately, some individuals have persistent viral replication despite antiviral therapy, with the resultant risks of antiviral resistance emergence and persistent illness [4, 12] . In this case series, we documented the recovery of dual NA in- hibitor-and M2 inhibitor-resistant mutants in 2 patients; a novel influenza B virus mutation conferring reduced NA inhibitor susceptibility; and the first instance, to our knowledge, of oseltamivir prophylaxis failure related to the detection of a resistant variant. Viruses in all 3 patients had transient changes in the NA genes. Two patients shed virus with the previously recognized Glu119Val mutation, which confers oseltamivir resistance in N2-containing viruses but does not affect susceptibility to zanamivir [4, 12, 13] . One patient was infected with influenza B virus that had an Asp198Asn mutation, which conferred reduced susceptibility to both oseltamivir and zanamivir [4] . Because oseltamivir is less active against influenza B virus NA, modest reductions in susceptibility may confer clinical resistance and may account for the prophylaxis failure in this patient. In 2 patients infected with influenza A virus, mutations indicative of dual resistance to oseltamivir and M2 inhibitors emerged. Both shed viruses with the Ser31Asn mutation, the most common mutation recognized in influenza A/H3N2 [14] . However, NA inhibitor resistance disappeared after cessation of oseltamivir treatment, whereas M2 inhibitor resistance was persistent. As was seen in patient 2, shedding of M2 inhibitor-resistant virus for months has been documented previously [12] . These findings are consistent with previous reports that NA inhibitor-resistant variants are less fit than are wild-type viruses [13] , whereas M2 inhibitor-resistant variants retain fitness.
We also documented that all 3 NA inhibitor-resistant viruses had changes in HA. The aa 226 substitution has the potential to reduce the efficiency of virus binding to cells, because it belongs to the HA receptor-binding site [10] . The other substitutions, at aa 142 and 195, are close to the receptor-binding site and have the potential to alter the virus requirement for NA activity. The clinical relevance of substitutions in HA is uncertain, and they have been uncommonly documented previously [9] . In cell culture, HA changes reduce virus susceptibility to NA inhibitors by lowering requirements for NA activity.
Interestingly, there were mixed populations of mutant and wild-type virus isolated from all 3 patients in the present study. This might indicate that the virus variant that emerged did not have a strong growth advantage while exposed to drug. Alternatively, it is also possible that propagation of the virus in cell culture altered the original ratio between resistant and wildtype variants.
Our findings provide potential insights into the management of immunocompromised patients with influenza [4] . All 3 patients were severely immunocompromised, which suggests that the degree of immunosuppression contributed to the lack of viral clearance. None of the patients had documented clearance of influenza virus before discontinuation of antiviral therapy. If possible, immunosuppressed patients should be managed with a tailored approach directed by sequential monitoring for viral replication and resistance testing when replication persists. Combination NA inhibitor and M2 inhibitor therapy shows enhanced antiviral activity in vitro and in vivo [15] , but it remains to be determined whether it reduces resistance emergence. New surveillance data [16] indicate that 92% of this season's H3N2 isolates and 25% of this season's H1N1 isolates are resistant to M2 inhibitors because of a Ser31Asn mutation in the M2 protein.
Consequently, therapy with M2 inhibitors alone or in combination would not be appropriate. Other combinations to consider in immunocompromised hosts include dual NA inhibi-tors or, possibly, an NA inhibitor and ribavirin, although further studies in animal models are needed. Theoretically, using higher oseltamivir doses (150 mg twice daily) may be associated with greater antiviral effects and, possibly, may reduce the emergence of resistance by providing higher blood concentrations [1] . In addition, vaccination of transplant recipients and their close contacts and consideration of seasonal antiviral chemoprophylaxis in highly immunocompromised persons might prevent a potentially fatal influenza virus infection; patients 1 and 3 were not vaccinated, which suggests that further work is needed to increase vaccination of these at-risk populations.
